SLBT

SL Science Holding Ltd

1.60

Oct 01 • 3:59 PM ET -0.10 (-5.88%)

1.72

Aftermarket • 5:13 PM ET +0.12 (7.78%)

Healthcare Biotechnology Taiwan Small NASD

Peers: SRPT IMCR BCAX MRVI ANAB TYRA ZYME FTRE LKFT RXRX

Index	-
Market Cap	897.22M
Enterprise Value	-
Income	-
Sales	-
Book/sh	-
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jun 15, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	-
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	59.54%
Insider Trans	1.38%
Inst Own	0.11%
Inst Trans	114.24%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-20.10%
SMA50	-35.24%
SMA200	-49.78%
Trades

Shs Outstand	560.76M
Shs Float	226.91M
Short Float	0.01%
Short Ratio	0.25
Short Interest	0.03M
52W High	14.50 -88.97%
52W Low	1.42 12.68%
Volatility	14.27% 12.36%
ATR (14)	0.23
RSI (14)	35.48
Beta	-
Rel Volume	0.31
Avg Volume	107.92K
Volume	33,673

Perf Week	2.56%
Perf Month	-42.65%
Perf Quarter	-73.29%
Perf Half Y	-
Perf YTD	-60.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.70
Price	1.60
Change %	-5.88%

Sep-24-26 08:00AM	SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing ?d T Cells Target Chemotherapy-Resistant Glioblastoma (GlobeNewswire) -6.02%
Sep-02-26 04:10PM	SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company (GlobeNewswire) +18.64%
Aug-27-26 08:00AM	SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform (GlobeNewswire)
Aug-11-26 08:00AM	SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of ?d T Cell Therapy in Glioblastoma (GlobeNewswire) -5.65%
Jul-17-26 08:00AM	SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology (GlobeNewswire)
08:00AM	Loading…
Jul-10-26 08:00AM	SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma (GlobeNewswire)
Jun-18-26 05:13PM	SL Science Holding Limited Reports Full Year 2025 Financial Results (GlobeNewswire) -9.25% -21.93%

SL Science Holding Ltd. operates as a biomedical company. It operates through Exosome products, CD-19 Armed-T products, GDT cell therapy products, corporate and unallocated segments. The firm offers immune cell development, skincare product formulations, cellular and gene therapies. The company was founded by Ching Dong Wang on March 18, 2025 and is headquartered in Taipei, Taiwan.

FounderMr. Ching-Dong Wang

CFO & DirectorMr. Ray Leung

CTO & DirectorDr. Ethan Shen Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wang Ching-Dong	Chief Executive Officer	Sep 29 '26	Buy	2272653.00	4,545,306	10,329,903,316,818	333,832,129	Oct 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLBT

SL Science Holding Ltd

Upgrade your Finviz experience